Eduardo Bruno Martins
CIK 1670431 · View on SEC EDGAR ↗
First SEC filing: July 13, 2023 · Latest: July 13, 2023
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 10, 2026 | SGMT | S | 3,640 | $5.36 | $19,510 | 103,296 Direct | -3.40% | Disposed | 90.9% (price as of 2026-08-21) |
| July 21, 2025 | SGMT | S | 8,277 | $9.13 | $75,569 | 106,936 Direct | -7.18% | Disposed | 12.0% (price as of 2026-08-21) |
| July 19, 2024 | SGMT | S | 8,357 | $3.10 | $25,907 | 81,213 Direct | -9.33% | Disposed | 230.0% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 19, 2026 | SGMT | Stock Option (Right to Buy) | Series A Common Stock (88,000) | $5.38 | Feb. 18, 2036 | 88,000 | Acquired |
| Feb. 6, 2025 | SGMT | Stock Option (Right to Buy) | Series A Common Stock (138,000) | $4.71 | Feb. 5, 2035 | 138,000 | Acquired |
| July 18, 2023 | SGMT | Stock Option (Right to Buy) | Series A Common Stock (44,009) | $13.51 | April 19, 2033 | 44,009 | Acquired |
| July 18, 2023 | SGMT | Stock Option (Right to Buy) | Common Stock (44,009) | $13.51 | April 19, 2033 | 44,009 | Disposed |
| July 18, 2023 | SGMT | Stock Option (Right to Buy) | Series A Common Stock (198,132) | $6.36 | Feb. 18, 2031 | 198,132 | Acquired |
| July 18, 2023 | SGMT | Stock Option (Right to Buy) | Common Stock (198,132) | $6.36 | Feb. 18, 2031 | 198,132 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
SGMT
M.D., D.Phil., Former Chief Medical Officer(7)| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $475,000 | — | — | — | $190,000 | — | $4,064 | $669,064 |
| 2023 | $442,930 | — | $265,127 | $594,620 | $202,840 | — | $3,564 | $1,509,081 |
| 2022 | $411,083 | — | — | — | $125,750 | — | $297 | $537,130 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.